Pyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments
June 08, 2021 08:00 ET
|
Pyxis Oncology
– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations – – Ritu Shah, PMP, appointed as Chief Operating Officer,...
Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
May 25, 2021 08:00 ET
|
Pyxis Oncology
LEXINGTON, Mass. and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Alloy Therapeutics (“Alloy”) and Pyxis Oncology ("Pyxis") today announced the formation of a joint venture named Kyma...
Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential
April 27, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional...
Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates
April 19, 2021 09:03 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on...
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
March 30, 2021 08:00 ET
|
Pyxis Oncology
-- New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point -- -- In addition to recently announced...
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
March 18, 2021 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for...